Galectin Therapeutics reports Q2 EPS (12c) vs (20c) last year

Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics (GALT), stated “We are encouraged by the continued analysis of data from our NAVIGATE trial , which further supports the clinical profile of belapectin in patients with MASH cirrhosis. At the European Association for the Study of the Liver in May, we presented a clinically significant response in Fibroscan and additional Fibroscan data outcomes supporting the NAVIGATE trial’s primary endpoint, the prevention of esophageal varices after 18 months of treatment with belapectin. We believe it is especially promising that these findings remain robust in patients who received belapectin beyond 18 months, reinforcing our belief in the potential of belapectin to modify disease progression in this high-risk population. We are also analyzing additional biomarkers and expect to present those results later this year.”